Weidman’s appointment goes into effect on June 8, 2026. He succeeds Stuart Randle, who held the corner office in an interim capacity after the company ousted CEO Liam Kelly in January. The company plans for Randle to continue serving on the board, with Weidman set to join the board when his appointment goes into effect.
With more than 25 years of industry experience, Weidman brings a track record of building and scaling businesses globally. He most recently served as SVP and president of Coronary and Renal Denervation at Medtronic, as well as holding the post of SVP and president of Aortic, Peripheral and Venous.
At the medtech giant, he oversaw significant growth and expansion of multi-billion dollar revenue operating units. Under his leadership, for example, Medtronic became one of the first companies to bring a renal denervation therapy for hypertension to market with its Symplicity Spyral system.
Weidman joins Wayne, Pennsylvania-based Teleflex at a time of significant change. The company continues to move forward with the planned sale of its Acute Care, Interventional Urology and OEM businesses in two separate deals worth a combined $2.03 billion. However, it faces shareholder backlash following this move and Kelly’s departure, with shareholders recently urging the company to engage potential buyers.
Commentary from Teleflex officials and its incoming CEO
Dr. Stephen Klasko, Teleflex board chair, said:
“We’re thrilled to welcome Jason to Teleflex. Following the completion of the divestitures, Teleflex will be a fundamentally transformed company, with a portfolio focused on our core interventional, critical care and high acuity hospital markets. Jason’s medical technology expertise is closely aligned with our focused product portfolio, and his track record of driving growth, advancing product innovations and expanding global markets make him an ideal candidate to lead Teleflex’s go-forward strategy. With attractive, high-growth end markets, what will be a significantly enhanced capital structure from our intended $1 billion share buyback and $800 million debt paydown following the close of the sale transactions and an experienced and driven leadership team, we believe Teleflex will be an incredibly compelling growth story.”
Weidman said:
“It’s an honor for me to join Teleflex at such an important inflection point and to help lead the Company into its next phase of growth. Having spent my entire career in the medical technology industry, I see a clear opportunity for Teleflex to build on its strong foundation and commitment to innovation, further shaping the future of healthcare while advancing our purpose of improving the health and quality of people’s lives.”
